局部应用辛伐他汀辅助促进大鼠脊柱融合
研究在大鼠脊柱融合模型中局部递送辛伐他汀,采用PLGA纳米粒载药,评价体外成骨分化与体内融合效果。结果显示辛伐他汀纳米粒组X线评分和融合率均高于空白纳米粒组,微CT骨量增加,作者认为辛伐他汀可能成为脊柱融合的安全、经济的骨合成代谢剂。
要点
- 辛伐他汀纳米粒体外释放效率74.1%,约50%释放发生在前1天。
- 辛伐他汀及辛伐他汀纳米粒处理细胞骨桥蛋白和骨钙素表达显著增高。
- 辛伐他汀纳米粒组融合率42.9% vs 空白纳米粒组0%(p=0.006)。
核心结论
- 通过PLGA纳米粒可实现辛伐他汀的持续释放,辛伐他汀纳米粒可诱导矿化增加及骨形成标志物升高。
- X线分析、微CT定量和盲法手动融合评估显示辛伐他汀纳米粒组较载体对照组骨形成和融合块强度显著增加。
- 作者认为辛伐他汀可能是脊柱融合中安全、经济的骨合成代谢剂。
研究设计与样本
- 基础科学研究,采用大鼠脊柱融合模型。
- 制备载辛伐他汀的PLGA纳米粒(SimNP)和不含辛伐他汀的纳米粒(BlankNP),并表征药物释放。
- 体外用MC3T3-E1细胞在含SimNP或BlankNP的分化培养基中培养,分析成骨细胞分化。
- 40只12周龄远交系雄性Wistar大鼠接受无内固定后外侧融合,使用髂嵴骨移植联合BlankNP、SimNP或辛伐他汀药物。
- 术后4周和9周行X线评估骨形成,9周处死取脊柱行微CT分析和盲法手动融合评估(MAF)。
主要发现
- SimNP释放效率为74.1%,约50%的释放发生在前1天。
- 辛伐他汀和SimNP处理的细胞骨桥蛋白(OPN)和骨钙素(OCN)表达显著增高。
- 微CT分析显示SimNP组动物骨体积和骨体积百分比(骨体积/总体积)高于对照组动物。
- SimNP组大鼠X线评分在4周(p=0.010)和9周(p<0.001)均高于BlankNP组。
- MAF显示SimNP组融合率高于BlankNP组(42.9% vs 0%,p=0.006)。
关键数值与推荐
- SimNP释放效率74.1%,约50%释放发生在前1天。
- SimNP组融合率42.9% vs BlankNP组0%(p=0.006)。
- SimNP组X线评分4周p=0.010、9周p<0.001,均高于BlankNP组。
- 微CT显示SimNP组骨体积和骨体积百分比高于对照组。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Basic Science. OBJECTIVE: To determine if locally delivered simvastatin can enhance bone formation in a rat spinal fusion model. SUMMARY OF BACKGROUND DATA: The bone-anabolic properties of statins in fracture healing are well established, however, few studies have evaluated the impact of locally delivered statins in spinal fusion. METHODS: We formulated poly(lactic-co-glycolic acid) (PLGA) nanoparticles by adapting previously published techniques. Two types of nanoparticles were created: simvastatin nanoparticles (SimNP) and nanoparticles without simvastatin (BlankNP). Drug elution from SimNP was characterized. Osteoblastic differentiation was analyzed using MC3T3-E1 cells cultured in differentiation medium containing SimNP or BlankNP. Forty male 12 week old outbred Wistar rats underwent uninstrumented posterolateral fusion using iliac crest bone graft and BlankNP, SimNP or simvastatin drug. X-rays to assess bone formation were obtained at 4 weeks and 9 weeks post-operatively. Spines were explanted at 9 weeks for micro-CT analysis, and a blinded manual assessment of fusion (MAF). RESULTS: SimNP achieved a release efficiency of 74.1% with ∼50% release occurring in the first day. Simvastatin and SimNP treated cells showed significantly greater expression of osteopontin (OPN) and osteocalcin (OCN). On micro-CT analysis, SimNP animals had higher bone volume and percent bone volume (bone volume/total volume) than control animals. SimNP rats had higher X-ray scores at 4 weeks (p=0.010) and 9 weeks (p<0.001) relative to BlankNP. MAF showed that SimNP had a higher fusion rate than BlankNP (42.9% vs. 0%, p=0.006). CONCLUSION: We were able to validate that sustained release of simvastatin via a PLGA nanoparticle. SimNP was able to induce an increase in mineralization as well as an increase in markers of bone formation. X-ray analysis, micro-CT quantification, and MAF assessment of SimNP treated rats showed significantly greater bone formation and fusion mass strength relative to vehicle treated animals. Simvastatin may be a safe, cost-effective bone anabolic agent for use in spinal fusion. LEVEL OF EVIDENCE: N/A.
引用
- Iyer S, Donnelly PE, Spaniel G, et al. Locally Applied Simvastatin as an Adjunct to Promote Spinal Fusion in Rats. Spine (Phila Pa 1976). 2019. PMID: 30896582. doi:10.1097/BRS.0000000000003020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。